Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vyome Holdings, IncHIND · Entity 1824 | Director | November 13, 2025 | November 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vyome Holdings, Inc
Report date November 13, 2025 · Filed November 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2035-07-30 | Direct | 17,833 |
Reported balance
After 2025-11-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-13 · Grant · Acquired 17,833 · Balance 17,833 F1: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. F2: Pursuant to the Merger Agreement the reporting person was granted 17,833 options to purchase shares of the Issuer's common stock. Of these, 4,458 options were fully vested as of the grant date. The remaining 13,375 options shall vest in twelve equal monthly installments beginning on November 30, 2025, subject to the Reporting Person's continued service on each vesting date. The options were granted under the Issuer's 2025 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc.
F2: Pursuant to the Merger Agreement the reporting person was granted 17,833 options to purchase shares of the Issuer's common stock. Of these, 4,458 options were fully vested as of the grant date. The remaining 13,375 options shall vest in twelve equal monthly installments beginning on November 30, 2025, subject to the Reporting Person's continued service on each vesting date. The options were granted under the Issuer's 2025 Equity Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2025 Filed Nov 18, 2025 02:11 UTC | Vyome Holdings, Inc HIND · Entity 1824 | GrantStock Option (right to buy) · Derivative | 17,833 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001213900-25-111711 · ownership.xml · derivative · entry 1 Tincoff John M. III · CIK 0002085876 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,833 Underlying: Common Stock · 17,833 shares Expires 2035-07-30 F1 · security: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. F1 · kind: Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of Vyome Therapeutics outstanding immediately prior to the effective time of the Merger, whether vested or unvested, was automatically assumed by the Issuer and converted into options to purchase shares of the Issuer's common stock. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. F2 · derivative.exercise_date: Pursuant to the Merger Agreement the reporting person was granted 17,833 options to purchase shares of the Issuer's common stock. Of these, 4,458 options were fully vested as of the grant date. The remaining 13,375 options shall vest in twelve equal monthly installments beginning on November 30, 2025, subject to the Reporting Person's continued service on each vesting date. The options were granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.